AU2017227803B2 - Therapy for frontotemporal dementia - Google Patents

Therapy for frontotemporal dementia Download PDF

Info

Publication number
AU2017227803B2
AU2017227803B2 AU2017227803A AU2017227803A AU2017227803B2 AU 2017227803 B2 AU2017227803 B2 AU 2017227803B2 AU 2017227803 A AU2017227803 A AU 2017227803A AU 2017227803 A AU2017227803 A AU 2017227803A AU 2017227803 B2 AU2017227803 B2 AU 2017227803B2
Authority
AU
Australia
Prior art keywords
mammal
grn
aav
progranulin
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017227803A
Other languages
English (en)
Other versions
AU2017227803A1 (en
Inventor
Defne AMADO
Alice CHEN PLOTKIN
Beverly L. Davidson
Julianne REIDERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
University of Pennsylvania Penn
Original Assignee
Childrens Hospital of Philadelphia CHOP
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP, University of Pennsylvania Penn filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2017227803A1 publication Critical patent/AU2017227803A1/en
Application granted granted Critical
Publication of AU2017227803B2 publication Critical patent/AU2017227803B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2017227803A 2016-03-02 2017-03-02 Therapy for frontotemporal dementia Active AU2017227803B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302525P 2016-03-02 2016-03-02
US62/302,525 2016-03-02
PCT/US2017/020397 WO2017151884A1 (en) 2016-03-02 2017-03-02 Therapy for frontotemporal dementia

Publications (2)

Publication Number Publication Date
AU2017227803A1 AU2017227803A1 (en) 2018-10-25
AU2017227803B2 true AU2017227803B2 (en) 2024-05-02

Family

ID=59743281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017227803A Active AU2017227803B2 (en) 2016-03-02 2017-03-02 Therapy for frontotemporal dementia

Country Status (6)

Country Link
US (1) US20190328906A1 (enExample)
EP (1) EP3423109A4 (enExample)
JP (2) JP7436089B2 (enExample)
AU (1) AU2017227803B2 (enExample)
CA (1) CA3016314A1 (enExample)
WO (1) WO2017151884A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
JP7436089B2 (ja) * 2016-03-02 2024-02-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 前頭側頭型認知症の治療
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
BR112020006633A2 (pt) 2017-10-03 2020-10-06 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
JP7361037B2 (ja) * 2017-10-03 2023-10-13 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
KR20200075865A (ko) * 2017-10-23 2020-06-26 프리베일 테라퓨틱스, 인크. 신경변성 질환에 대한 유전자 요법
CN118345115A (zh) * 2017-12-01 2024-07-16 编码治疗公司 工程化的dna结合蛋白
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
CN113164627B (zh) * 2018-10-16 2024-10-29 戴纳立制药公司 治疗和监测颗粒体蛋白前体相关病症的方法
EP3917539A4 (en) * 2019-02-01 2022-11-23 Avrobio, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
JP7637058B2 (ja) * 2019-02-22 2025-02-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
KR20210150486A (ko) 2019-04-10 2021-12-10 프리베일 테라퓨틱스, 인크. 리소좀 장애에 대한 유전자 요법
MX2021012184A (es) 2019-04-10 2022-01-24 Prevail Therapeutics Inc Terapias genicas para trastornos lisosomales.
GB201913974D0 (en) 2019-09-27 2019-11-13 King S College London Vector
AU2020371662A1 (en) * 2019-10-22 2022-05-12 Applied Genetic Technologies Corporation Adeno-associated virus (AAV) systems for treatment of progranulin associated neurodegenerative diseases or disorders
US20230193212A1 (en) * 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
AU2021280943A1 (en) * 2020-05-27 2022-07-28 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
EP4192517A1 (en) * 2020-08-10 2023-06-14 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders
IL300294A (en) * 2020-08-12 2023-04-01 UCB Biopharma SRL Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences
WO2022046988A1 (en) * 2020-08-26 2022-03-03 The Trustees Of The University Of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
AU2022214429A1 (en) 2021-02-01 2023-09-14 Tern Therapeutics, Llc Gene therapy for neuronal ceroid lipofuscinoses
WO2024035649A1 (en) * 2022-08-08 2024-02-15 Shape Therapeutics Inc. Compositions for progranulin expression and methods of use thereof
GB202216168D0 (en) 2022-10-31 2022-12-14 UCB Biopharma SRL Route of administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146046A2 (en) * 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2010129021A1 (en) * 2009-05-02 2010-11-11 Genzyme Corporation Gene therapy for neurodegenerative disorders
US20100324127A1 (en) * 2008-01-16 2010-12-23 Kay Denis G Treating neurodegenerative diseases with progranulin
US20110203007A1 (en) * 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436089B2 (ja) * 2016-03-02 2024-02-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 前頭側頭型認知症の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146046A2 (en) * 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
US20100324127A1 (en) * 2008-01-16 2010-12-23 Kay Denis G Treating neurodegenerative diseases with progranulin
WO2010129021A1 (en) * 2009-05-02 2010-11-11 Genzyme Corporation Gene therapy for neurodegenerative disorders
US20110203007A1 (en) * 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
De Muynck, L. & Van Damme, P., Frontiers of Clinical Drug research - Alzheimer Disorders, (2015), vol. 3, pages 231-291, doi: 10.2174/97816810806801150301 *

Also Published As

Publication number Publication date
US20190328906A1 (en) 2019-10-31
EP3423109A1 (en) 2019-01-09
CA3016314A1 (en) 2017-09-08
EP3423109A4 (en) 2019-08-14
JP7507808B2 (ja) 2024-06-28
JP2019511570A (ja) 2019-04-25
JP2022071067A (ja) 2022-05-13
WO2017151884A1 (en) 2017-09-08
AU2017227803A1 (en) 2018-10-25
JP7436089B2 (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
AU2017227803B2 (en) Therapy for frontotemporal dementia
EP3364970B1 (en) Gene therapy for use in treating lysosomal storage disease
US12221635B2 (en) Sulfamidase (SGSH) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type IIIA (MPS IIIA)
JP2023002721A (ja) 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用
CN113438954A (zh) 可用于治疗gm1神经节苷脂病的组合物
US12404523B2 (en) Adeno-associated virus delivery of CLN3 polynucleotide
CA3127889A1 (en) Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2
CN113574176A (zh) 腺相关病毒对cln6多核苷酸的递送
US20240156988A1 (en) Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same
WO2025231406A1 (en) Methods to increase transduction of ependyma cells in brain
WO2025213097A1 (en) Novel gene therapy constructs for stxbp1 haploinsufficiency
HK40064267A (en) Adeno-associated virus delivery of cln3 polynucleotide
HK40063258A (en) Adeno-associated virus delivery of cln6 polynucleotide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)